Jaguar Animal Health (JAGX) Continues its Sizzling Year +82%

Edward Kim  |

Shares in Jaguar Animal Health, Inc. (JAGX) an animal health company focused on developing and commercializing first-in-class gastrointestinal products has had a sizzling 2017 and its run continues today. The company focuses on companion and production animals, foals, and high value horses, and they recently announced the publication of a study titled “Prophylactic use of a standardized botanical extract for the prevention of naturally occurring diarrhea in newborn Holstein calves” in the official journal of the American Dairy Science Association, Journal of Dairy Science—a leading peer-reviewed general dairy research journal. The study was conducted by researchers from Cornell University College of Veterinary Medicine. Jaguar plans to launch the prophylactic formulation of Neonorm Calf this year in powder form for administration in liquid.

Neonorm Calf, one of Jaguar’s lead non-prescription products, has been formulated and clinically tested to help proactively retain fluid in dairy calves and reduce the severity of diarrhea—aiding the animals in avoiding debilitating, dangerous levels of dehydration associated with scours. The powder form of the product allows for ease of administration for herd-wide management.

See a 3 month chart below for JAGX (cover photo attribute to Wikipedia)


----------------------------------------------------------

We will be rolling our our portfolio in upcoming weeks one sector at a time...sign up below or ping us at the email below.

------------------------

Email me content@equities.com if you are a Public Company and would like to see our Testimonials

Click Here if you are an Investor and want to sign up for our Friday Newsletter

Click Here to be part of the Equities.com Database you can also reach us at research@equities.com

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Trending Articles

Bond Yields Have Risen Well Above Stock Dividend Yields. Are They a Buy?
We're at the Tail End of a Classic Video Game Stock Bust
Is Gold Really the Right Place for Your Money?
How Companies Can Succeed in AI Winter: Jeff Kagan
Utility Investing Is a Steady, Buy-and-Hold Play. Just Not in This Market
Why Nuclear Energy Is Now Part of The Road to Renewables
Our Inflation Nightmare Will Flatline in Six Months
California Wants 100% Electric Vehicles By 2035. Will Its Energy Grid Be Ready?

Market Movers

Sponsored Financial Content